Clinical Trials Directory

Trials / Completed

CompletedNCT01651156

Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema

Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Phase 3 Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Patients With Cardiac Edema Based on the Conventional Therapy

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
244 (actual)
Sponsor
Otsuka Beijing Research Institute · Industry
Sex
All
Age
20 Years – 85 Years
Healthy volunteers
Not accepted

Summary

A randomized, double-blind, multicenter, placebo-controlled, parallel study to evaluate the efficacy and safety of Tolvaptan in the treatment of patients with cardiac edema (body fluid retention caused by congestive heart failure) based on the conventional therapy. To evaluate the efficacy and safety of Tolvaptan 15 mg on congestive heart failure patients with body fluid retention after current diuretic treatment, after continuous treatment of 7 days' oral Tolvaptan 15mg or placebo.

Detailed description

* A randomized, double-blind, multicenter, placebo-controlled, parallel study * Study population: The congestive heart failure patients with body fluid retention after received current diuretics therapy * Number of patients: Patients will be randomly assigned to Tolvaptan and placebo group in 1:1 ratio, 120 patients in each group, 240 patients in total * Group assignment method: Tolvaptan 15 mg group: conventional therapy + Tolvaptan 15 mg Placebo group: conventional therapy + placebo * Administration and dosage of the study drug: Once daily, 1 tablet be taken orally after breakfast, for successive 7 days * Study period: * Screening period (4 days in minimum, 7 days in maximum), including: Screening period: from the time the informed consent form is signed to Day -4 Observation period: 3 days before drug administration * Treatment period: 7 days * Follow up visits: Day 8 (efficacy evaluation day) and Day 7 (+3) after the last dosing * Post treatment survey: Day 14 (+3) after the last dosing

Conditions

Interventions

TypeNameDescription
DRUGTolvaptanoral taken
DRUGPlacebo

Timeline

Start date
2012-07-01
Primary completion
2013-07-01
Completion
2013-07-01
First posted
2012-07-26
Last updated
2013-12-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01651156. Inclusion in this directory is not an endorsement.